Advaxis, Inc. Release: University of Pennsylvania Doses First Two Dogs in ADXS-HER2 Canine Osteosarcoma Study

Published: Aug 02, 2012

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the first two dogs have been dosed in the University of Pennsylvania School of Veterinary Medicine study of ADXS-HER2 for canine osteosarcoma.

Back to news